Predicting pharmacokinetic herb-drug interactions.
In vitro and in vivo studies have indicated that the induction or inhibition of cytochrome P450 (CYP) is one of the major mechanisms for some clinically important pharmacokinetic herb-drug interactions. Thus, an attempt was made to predict pharmacokinetic herb-drug interactions using the pharmacokinetic principles that are used for predicting drug-drug interactions. The expected AUC ratio was mainly dependent on unbound herbal inhibitor concentration ([I]) and inhibition constant (Ki), hepatic fraction (fh), number of inhibitory herbal constituents (n) and metabolic pathway fraction in hepatic metabolism (fm). Herb-drug interactions would be with low risk if sigma(i=1)n [[Ii]/Ki(i)] is less than 0.1, medium risk if it is between 0.1 and 1.0, and high risk if it is greater than 1. For high clearance drugs, the change of fh x fm had minor influence on AUC ratio when sigma(i=1)n [[Ii]/Ki(i)] values were fixed. Similarly, fm did not affect the AUC ratio for low clearance drugs. It appeared likely to predict a herb-drug metabolic interaction when [I], Ki, fh, fm and n could be determined. However, many herb- and drug-related factors may cause difficulties with the prediction, and well-designed human studies are always necessary.
Zhou
Shufeng
S
Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. phazsf@nus.edu.sg
Chan
Eli
E
Li
Shu Chuen
SC
Huang
Min
M
Chen
Xiao
X
Li
Xiaotian
X
Zhang
Qiang
Q
Paxton
James W
JW
D019540:Area Under Curve; D003577:Cytochrome P-450 Enzyme System / Q000493:pharmacokinetics*; D020441:Ginkgo biloba / Q000378:metabolism*; D041743:Herb-Drug Interactions; D006801:Humans; D020902:Hypericum / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D020944:Silybum marianum / Q000378:metabolism*; D012307:Risk Factors
D003577:Cytochrome P-450 Enzyme System